Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Stock Information for Corbus Pharmaceuticals Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit
Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer
Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
Corbus Pharmaceuticals Announces Pricing of Public Offering

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.